Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
4.170
+0.070 (1.71%)
At close: Aug 1, 2025, 4:00 PM
4.159
-0.011 (-0.26%)
After-hours: Aug 1, 2025, 7:57 PM EDT
Aspen Technology Employees
Atai Life Sciences had 54 employees as of December 31, 2024. The number of employees decreased by 29 or -34.94% compared to the previous year.
Employees
54
Change (1Y)
-29
Growth (1Y)
-34.94%
Revenue / Employee
$34,500
Profits / Employee
-$2,759,019
Market Cap
884.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54 | -29 | -34.94% |
| Dec 31, 2023 | 83 | -50 | -37.59% |
| Dec 31, 2022 | 133 | 46 | 52.87% |
| Dec 31, 2021 | 87 | 52 | 148.57% |
| Dec 31, 2020 | 35 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATAI News
- 4 days ago - Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus - Seeking Alpha
- 4 days ago - Why Is ATAI Life Sciences Stock Trading Lower On Monday? - Benzinga
- 4 days ago - ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 7 days ago - Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial - Reuters
- 7 days ago - Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia - GlobeNewsWire
- 4 weeks ago - Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD - Seeking Alpha
- 4 weeks ago - Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data - Benzinga
- 4 weeks ago - atai Life Sciences Announces $50 Million Private Placement Financing - GlobeNewsWire